Trials / Completed
CompletedNCT00481962
Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)
Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tygacil | Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-06-04
- Last updated
- 2009-09-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00481962. Inclusion in this directory is not an endorsement.